CL2021003366A1 - Receptores de linfocitos t de mage-a4 y métodos de uso de estos. - Google Patents

Receptores de linfocitos t de mage-a4 y métodos de uso de estos.

Info

Publication number
CL2021003366A1
CL2021003366A1 CL2021003366A CL2021003366A CL2021003366A1 CL 2021003366 A1 CL2021003366 A1 CL 2021003366A1 CL 2021003366 A CL2021003366 A CL 2021003366A CL 2021003366 A CL2021003366 A CL 2021003366A CL 2021003366 A1 CL2021003366 A1 CL 2021003366A1
Authority
CL
Chile
Prior art keywords
mage
cell receptors
methods
tcrs
hla
Prior art date
Application number
CL2021003366A
Other languages
English (en)
Spanish (es)
Inventor
Natalie Bowerman
Cagan Gurer
Johanna Hansen
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2021003366A1 publication Critical patent/CL2021003366A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
CL2021003366A 2019-06-18 2021-12-15 Receptores de linfocitos t de mage-a4 y métodos de uso de estos. CL2021003366A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962862726P 2019-06-18 2019-06-18
US201962871793P 2019-07-09 2019-07-09

Publications (1)

Publication Number Publication Date
CL2021003366A1 true CL2021003366A1 (es) 2022-08-19

Family

ID=74040867

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2021003366A CL2021003366A1 (es) 2019-06-18 2021-12-15 Receptores de linfocitos t de mage-a4 y métodos de uso de estos.
CL2024000119A CL2024000119A1 (es) 2019-06-18 2024-01-15 Receptores de linfocitos t de mage-a4 y métodos de uso de estos

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2024000119A CL2024000119A1 (es) 2019-06-18 2024-01-15 Receptores de linfocitos t de mage-a4 y métodos de uso de estos

Country Status (15)

Country Link
US (1) US20220324939A1 (https=)
EP (1) EP3986938A4 (https=)
JP (3) JP7730765B2 (https=)
KR (1) KR20220035387A (https=)
CN (2) CN118994364A (https=)
AU (1) AU2020295401A1 (https=)
BR (1) BR112021025548A2 (https=)
CA (1) CA3144253A1 (https=)
CL (2) CL2021003366A1 (https=)
CO (1) CO2022000281A2 (https=)
IL (1) IL289042A (https=)
MA (1) MA56548A (https=)
MX (1) MX2021015946A (https=)
PH (1) PH12021553152A1 (https=)
WO (1) WO2020257288A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
SG11201901634UA (en) * 2016-09-23 2019-04-29 Lion Tcr Pte Ltd An hbv antigen specific binding molecules and fragments thereof
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
PH12021553152A1 (en) * 2019-06-18 2022-08-15 Regeneron Pharma Mage-a4 t cell receptors and methods of use thereof
CN113621070A (zh) 2020-05-06 2021-11-09 华夏英泰（北京）生物技术有限公司 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用
TW202229327A (zh) * 2020-10-02 2022-08-01 美國衛生與公眾服務部 針對含有g13d突變之ras之hla第ii類限制性dq t細胞受體
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
MX2023010541A (es) 2021-03-09 2023-11-24 Cdr Life Ag Proteinas de union al antigeno del peptido del mhc mage-a4.
EP4422651A4 (en) * 2021-10-25 2025-12-17 Univ Texas PEPTIDES AND MANIPULATED T-CELL RECEPTORS FOR TARGETTING THE MAGE-A4 ANTIGEN AND METHOD FOR USE
EP4472742A1 (en) * 2022-02-03 2024-12-11 University College Cardiff Consultants Limited Novel t-cell receptor
WO2023238125A1 (en) * 2022-06-08 2023-12-14 Sheba Impact Ltd. Virus-specific recombinant t cell receptors and t cells comprising them
JP2025525382A (ja) * 2022-06-24 2025-08-05 アムジエン・インコーポレーテツド Ｍａｇｅａ４特異的ｔ細胞受容体
CA3264474A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag MAGE-A4 DOUBLE T LYMPHOCYTE ENGAGEMENT
JP2026509947A (ja) 2022-10-31 2026-03-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 養子細胞療法および標的化免疫サイトカインの組合せを用いてがんを処置する方法
EP4393942A1 (en) * 2022-12-29 2024-07-03 Keshihua (Nanjing) Biotechnology Co., Ltd Tcr, polypeptide, expression vector, host cell, pharmaceutical composition and method for obtaining tcr
AU2024214482A1 (en) 2023-02-03 2025-08-07 Zelluna Immunotherapy As Anti-mage-a4 t cell receptors
CN119569851A (zh) * 2023-09-05 2025-03-07 香雪生命科学技术（广东）有限公司 针对magea4的高亲和力tcr
WO2025233432A1 (en) * 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Use and dosage of an antigen-binding protein comprising a tcr specific for an hla-a*02 restricted peptide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311914B2 (en) * 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
NL2014935B1 (en) * 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
GB201604492D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
SMT202200306T1 (it) * 2016-04-08 2022-09-14 Immunocore Ltd Recettori di cellule t
BR112018070637A2 (pt) * 2016-04-08 2019-02-05 Adaptimmune Ltd receptores de células t
DK3440106T3 (da) * 2016-04-08 2021-10-04 Adaptimmune Ltd T-cellereceptorer
WO2020243134A1 (en) 2019-05-27 2020-12-03 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy
PH12021553152A1 (en) * 2019-06-18 2022-08-15 Regeneron Pharma Mage-a4 t cell receptors and methods of use thereof

Also Published As

Publication number Publication date
PH12021553152A1 (en) 2022-08-15
JP2024164066A (ja) 2024-11-26
KR20220035387A (ko) 2022-03-22
CN118994364A (zh) 2024-11-22
JP2022537359A (ja) 2022-08-25
CN114585646A (zh) 2022-06-03
JP7730765B2 (ja) 2025-08-28
WO2020257288A2 (en) 2020-12-24
BR112021025548A2 (pt) 2022-05-17
CA3144253A1 (en) 2020-12-24
US20220324939A1 (en) 2022-10-13
CN114585646B (zh) 2024-09-03
IL289042A (en) 2022-02-01
EP3986938A2 (en) 2022-04-27
MA56548A (fr) 2022-04-27
JP2025166209A (ja) 2025-11-05
AU2020295401A1 (en) 2022-02-10
WO2020257288A3 (en) 2021-04-08
EP3986938A4 (en) 2023-06-28
CO2022000281A2 (es) 2022-01-28
CL2024000119A1 (es) 2024-05-31
MX2021015946A (es) 2022-04-18

Similar Documents

Publication Publication Date Title
CO2022000281A2 (es) Receptores de linfocitos t de mage-a4 y métodos de uso de estos
CO2022011869A2 (es) Antígeno expresado preferentemente en receptores de linfocitos t de melanoma (prame) y sus métodos de uso
CL2022003264A1 (es) Péptidos y sus combinaciones para uso en inmunoterapia contra el cáncer de próstata y otros
CY1124835T1 (el) Βελτιωμενο πολυπεπτιδικο μοριο διπλης ειδικοτητας
WO2020086647A8 (en) Ny-eso-1 t cell receptors and methods of use thereof
MX2019008346A (es) Receptores de celulas t que se unen a ny-eso-1 y metodos de uso de estos.
CO2018010538A2 (es) Anticuerpos específicos del receptor de poliovirus humano (rvp)
CY1121962T1 (el) Υποδοχεις τ κυτταρου
CL2018002859A1 (es) Receptores de células t.
SA519410362B1 (ar) مستقبل للخلايا التائية (tcr) وببتيدات
CO2020000214A2 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
CL2021001779A1 (es) Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismos
CO2019003809A2 (es) Anticuerpos contra proteína alfa reguladora de señal y métodos de uso
MX2016010856A (es) Metodo.
CO2019013654A2 (es) Receptores de antígenos quiméricos que se dirigen a flt3
CR20190477A (es) Versión optimizada para fc de anticuerpo anti-cd25 para la reducción celular específica de tumor
MX2017001599A (es) Anticuerpos novedosos y sus usos.
MX2016008193A (es) Anticuerpos y fragmentos anti-vista.
CL2019002949A1 (es) Nuevos péptidos y combinación de péptidos para el uso de la inmunoterapia contra varios tipos de cáncer. (divisional solicitud 201801533)
CL2019002081A1 (es) Proteínas de unión al receptor de glucagón y métodos para usarlas.
MX2025014061A (es) Receptores de linfocitos t que se unen a los peptidos presentados de hpv16, mart1, cmv, ebv o influenza
CL2023003299A1 (es) Terapia de células t con receptor de antígeno quimérico específico de cd19
CR20160339A (es) Anticuerpos y fragmentos anti-vista